このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

月経困難症の女性における非ステロイド性抗炎症薬(NSAID)反応と痛みの中枢性感作

2026年8月26日 更新者:Laura Payne、Mclean Hospital

Menstrual pain is the most common gynecological complaint and the leading cause of school and work absences in reproductive-age girls and women. One of the primary treatments for menstrual pain is use of nonsteroidal anti-inflammatory drugs (NSAIDs; over-the-counter medications such as naproxen, ibuprofen, or aspirin), although up to 18% of women do not get pain relief from these medications. One reason for this may be due to central sensitization of pain, which is when alterations in the central nervous system change how pain is processed in the brain and experienced. Determining the role of central sensitization in menstrual pain is important because central sensitization is associated with the development of chronic pain. Understanding the relationship between NSAID response and central sensitization is important because it could indicate women who may go on to develop chronic pain later in life. This study would directly address this question. Identifying women at risk for chronic pain would help target new treatments to this vulnerable group to ideally prevent pain from becoming chronic. This is particularly important for women in the military because the severity of menstrual pain is associated with missed work, such that in active-duty military women, less than 4.4% with mild menstrual pain missed work, whereas 20.7% of women with moderate to severe menstrual pain missed work. Addressing the significant impact of menstrual pain for military women will help reducing suffering and potentially decrease the risk of developing future chronic pain problems in this population.

調査の概要

研究の種類

介入

入学 (実際)

70

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Belmont、Massachusetts、アメリカ、02478
        • McLean Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~50年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Female aged 18-50 years
  2. Menstrual pain rated at least 6/10 on a 0 (no pain) to 10 (worst pain possible) NRS for all menstrual cycles in the previous 6 months
  3. Regular menstrual cycles over the past year (at least 9 in the previous 12 months)
  4. Self-reported menstrual cycle averaging 22-35 days
  5. Access to a smartphone and email, and willing/able to receive text messages
  6. Able to read and understand English
  7. Ability and willingness to provide written informed consent.

Exclusion Criteria:

  1. Use of oral contraceptives or any exogenous hormones in the previous 3 months prior to participation
  2. Variable levels of menstrual pain in the previous 6 months
  3. Self-reported symptoms consistent with a chronic pain condition (e.g., pain in any body area lasting longer than 3 months) or previous diagnosis of a chronic pain condition
  4. Currently pregnant or breastfeeding
  5. History of pelvic inflammatory disease or sexually transmitted disease
  6. Acute illness or injury that would potentially impact pain task performance (e.g., fever, flu symptoms) or that affect sensitivity of the extremities (e.g., Reynaud's disease)
  7. Allergy to naproxen or having a health condition that contradicts use of naproxen or affects naproxen metabolism (e.g., kidney disease)
  8. History of high blood pressure or anemia (due to possible complications from NSAID use).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sodium Naproxen first

Participants take the dose of sodium naproxen during the first menstrual cycle and take the placebo during the second menstrual cycle.

One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

実験的:Placebo first

Participants take the dose of placebo during the first menstrual cycle and take the sodium naproxen during the second menstrual cycle.

One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall Non-steroidal Anti-inflammatory Drug (NSAID) Response
時間枠:4 hrs after taking dose during the 2nd medicated menstrual period (i.e., 4 hrs after the first occurrence of pain >= 6 on the 0-10 scale after menstrual bleeding has started during the 2nd medicated menstrual period); # of days varies by participant

NSAID response will be calculated by comparing change in menstrual pain ratings following NSAID to change in menstrual pain ratings following placebo. Calculated by subtracting the placebo cycle response measure from the NSAID cycle response measure. This will result in a single measure indicative of the degree of NSAID response, while controlling for placebo effects. Possible range: -20 (min) to 20 (max). The value of each intervention separately can be associated with a better or worse outcome, as indicated below. The value of this measure is not independently clinically meaningful (i.e., not related to better or worse outcomes) as it is the result of comparing an individual to themself. Negative values indicate that the participant demonstrated more response to naproxen than they did to placebo; positive values indicate that the participant demonstrated more response to placebo than they did to naproxen.

4 hrs after taking dose during the 2nd medicated menstrual period (i.e., 4 hrs after the first occurrence of pain >= 6 on the 0-10 scale after menstrual bleeding has started during the 2nd medicated menstrual period); # of days varies by participant
Urinary Naproxen Concentration
時間枠:Four hours after taking the dose (either Naproxen or placebo).

Concentration of naproxen measured in the urine sample. Measured in nanograms of Naproxen Glucuronide per mg creatinine. Value is not independently clinically meaningful (i.e., not related to better or worse outcomes).

Four hours after taking the dose (either Naproxen or placebo).

二次結果の測定

結果測定
メジャーの説明
時間枠
Placebo Cycle Response
時間枠:4 hours after dose is taken.

Change in menstrual pain rating on a 0 (no pain) to 10 (worst pain possible) numeric rating scale before and after the dose is taken. Calculated by subtracting the pre-dose rating from the post-dose rating. Possible range: -10 (min) to 10 (max). Lower scores indicate better outcome.

4 hours after dose is taken.
Non-steroidal Anti-inflammatory Drug (NSAID) Cycle Response
時間枠:4 hours after dose is taken.

Change in menstrual pain rating on a 0 (no pain) to 10 (worst pain possible) numeric rating scale before and after the dose is taken. Calculated by subtracting the pre-dose rating from the post-dose rating. Possible range: -10 (min) to 10 (max). Lower scores indicate better outcome.

4 hours after dose is taken.
Urinary PGF2α Concentration
時間枠:Four hours after taking the dose (either Naproxen or placebo).

Concentration of prostaglandin F2α (PGF2α) measured in the urine sample. Value is not independently clinically meaningful (i.e., not related to better or worse outcomes).

Four hours after taking the dose (either Naproxen or placebo).
Urinary PGE Concentration
時間枠:Four hours after taking the dose (either Naproxen or placebo).

New information since initial submission indicated that this outcome measure (Prostaglandin E; PGE) would not be detectable in urine. No PGE analyses were conducted.

Four hours after taking the dose (either Naproxen or placebo).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Laura Payne, PhD、Mclean Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月25日

一次修了 (実際)

2025年8月1日

研究の完了 (実際)

2025年8月1日

試験登録日

最初に提出

2023年5月31日

QC基準を満たした最初の提出物

2023年6月8日

最初の投稿 (実際)

2023年6月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月22日

QC基準を満たした最後の更新が送信されました

2026年8月26日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する